| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/29/2004 | CA2498095A1 Method for extracting a natural mixture of conjugated equine estrogens that is depleted of non-conjugated lipophilic compounds |
| 04/29/2004 | CA2497262A1 Buccal polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
| 04/29/2004 | CA2475053A1 Treatment of microbial infections and associated gastrointestinal disorders with thymosin .beta.4 |
| 04/28/2004 | EP1413614A1 Method for producing fish gelatin peptide |
| 04/28/2004 | EP1413587A2 Modified complement system regulator |
| 04/28/2004 | EP1413583A2 Compounds that inhibit T cell proliferation and methods using the same |
| 04/28/2004 | EP1413581A1 Rapamycin derivatives |
| 04/28/2004 | EP1413331A2 Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) for vascular indications |
| 04/28/2004 | EP1413314A1 Medicinal compositions |
| 04/28/2004 | EP1413312A2 Therapeutic human albumin having a low aluminium binding activity |
| 04/28/2004 | EP1413311A1 Compositions for nasal administration of insulin |
| 04/28/2004 | EP1413297A1 Cyclosporin-containing soft capsule preparations |
| 04/28/2004 | EP1413292A1 Bioadhesive pharmaceutical compositions based on non-steroidal anti-inflammatory drugs |
| 04/28/2004 | EP1413174A1 Mounting arrangement for auxiliary burner or lance |
| 04/28/2004 | EP1412757A2 Method for identification of proteins from intracellular bacteria |
| 04/28/2004 | EP1412748A2 Mage-a3 peptides presented by hla class ii molecules |
| 04/28/2004 | EP1412527A2 Isp-1 and ctb-1 genes and uses thereof |
| 04/28/2004 | EP1412503A2 A fusion protein |
| 04/28/2004 | EP1412501A1 Hepatitis b virus pre-s1 derived synthetic polypeptides and uses thereof |
| 04/28/2004 | EP1412499A2 Cytokine polypeptides |
| 04/28/2004 | EP1412498A2 Polynucleotides expressed in dendritic cells and polypeptides encoded thereby |
| 04/28/2004 | EP1412492A2 Regulator of calcineurin |
| 04/28/2004 | EP1412490A1 Mediating the effects of alcohol consumption by orally administering active dry yeast |
| 04/28/2004 | EP1412482A2 Uses of opg ligand to modulate immune responses |
| 04/28/2004 | EP1412477A2 GPCs AS MODIFIERS OF THE IRRTK AND P21 PATHWAYS AND METHODS OF USE |
| 04/28/2004 | EP1412388A1 Humanized antibodies derived from dd-3b6/22, specific for the d-dimer fragment of fibrin |
| 04/28/2004 | EP1412387A2 Transporters and ion channels |
| 04/28/2004 | EP1412385A2 Modified insulin with reduced immunogenicity |
| 04/28/2004 | EP1412384A2 Stable formulation of modified glp-1 |
| 04/28/2004 | EP1412383A2 Peptides conjugates, their derivatives with metal complexes and use thereof for magnetic resonance imaging (mri) |
| 04/28/2004 | EP1412382A2 Interferon gamma polypeptide variants |
| 04/28/2004 | EP1412380A1 New cationic peptides of the dermaseptin family isolated from the skin secretion of phyllomedusa hypochondrialis |
| 04/28/2004 | EP1412377A1 Production of high molecular mass lectins |
| 04/28/2004 | EP1412374A2 Novel pgc-1 isoforms and uses therefor |
| 04/28/2004 | EP1412336A1 Peptoid compounds |
| 04/28/2004 | EP1412328A1 Dolastatin 10 derivatives |
| 04/28/2004 | EP1412324A2 Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
| 04/28/2004 | EP1411994A2 Compositions comprising bone marrow cells together with demineralized and/or mineralized bone matrix and uses thereof in the induction of bone and cartilage formation |
| 04/28/2004 | EP1411990A2 Modulation of antibody formation in mammals, applicability in gene therapy and animal model generation |
| 04/28/2004 | EP1411979A1 Vaccine comprising gp120 and nef and/or tat for the immunisation against hiv |
| 04/28/2004 | EP1411978A1 Botulinum toxin in the treatment or prevention of acne |
| 04/28/2004 | EP1411975A1 Methylation of histone h4 at arginine 3 |
| 04/28/2004 | EP1411973A1 Pharmaceutical composition comprising factor vii polypeptides and factor xi polypeptides |
| 04/28/2004 | EP1411972A2 Secretin for the treatment of asthma |
| 04/28/2004 | EP1411971A1 Use of long pentraxin ptx3 for treating female infertility |
| 04/28/2004 | EP1411970A2 Use of sarp-1 for the treatment and/or prevention of scleroderma |
| 04/28/2004 | EP1411969A1 Modified protamine with reduced immunogenicity |
| 04/28/2004 | EP1411968A2 Glp-1 exendin-4 peptide analogs and uses thereof |
| 04/28/2004 | EP1411967A2 Blocking peptide for inflammatory cell secretion |
| 04/28/2004 | EP1411965A1 Methods and compositions for controlling protein assembly or aggregation |
| 04/28/2004 | EP1411964A2 Peptides which modulate blood coagulation and methods of use thereof |
| 04/28/2004 | EP1411963A2 Cytotoxic factors for modulating cell death |
| 04/28/2004 | EP1411951A2 Enteral compositions for the prevention and/or treatment of sepsis |
| 04/28/2004 | EP1411928A1 Viral polymerase inhibitors |
| 04/28/2004 | EP1411926A1 Integrin inhibitors for the treatment of eye diseases |
| 04/28/2004 | EP1411924A1 Hypertension treatment |
| 04/28/2004 | EP1411918A2 Methods to mobilize progenitor/stem cells |
| 04/28/2004 | EP1411907A1 Inhibitors of hb-egf (erbb) receptors for treating myeloma |
| 04/28/2004 | EP1411905A1 Sustained release delivery system |
| 04/28/2004 | EP1411904A1 Sustained release pharmaceutical composition |
| 04/28/2004 | EP1411880A2 Recombinant vsv for the treatment of tumor cells |
| 04/28/2004 | EP1382688A9 Screening method |
| 04/28/2004 | EP1326628B1 Chemokine mutants in the treatment of multiple sclerosis |
| 04/28/2004 | EP1307539A4 Gene expression profile for kshv infection and methods for treating same |
| 04/28/2004 | EP1286684B1 use of cxcr4 antagonists for treating autoimmune diseases and cancer |
| 04/28/2004 | EP1255559B1 Use of inhibitors of caspase-3 or caspase-activated desoxyribonuclease (cad) for treating cardiac disease |
| 04/28/2004 | EP1250147B1 Interferon-alpha use in the treatment of ewing's sarcoma |
| 04/28/2004 | EP1150716B1 Pharmaceutical composition of hydrophobically modified hedgehog proteins and their use |
| 04/28/2004 | EP1137631B1 REVERSIBLE AQUEOUS pH SENSITIVE LIPIDIZING REAGENTS, COMPOSITIONS AND METHODS OF USE |
| 04/28/2004 | EP1128841B1 Pharmaceutical preparation containing a receptor-antagonist for treating blood-clotting disorders |
| 04/28/2004 | EP1061946B1 Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates |
| 04/28/2004 | EP1058555B1 Costimulatory blockade and mixed chimerism in allotransplantation |
| 04/28/2004 | EP1015484B1 Peptides derived from complement peptide c3a sequence and antiallergic compositions comprising them |
| 04/28/2004 | EP1012190A4 Eosinophil eotaxin receptor |
| 04/28/2004 | EP0988050B1 Utilization of wolinella succinogenes asparaginase to treat diseases associated with asparagine dependence |
| 04/28/2004 | EP0944723B1 Mammalian chemokines |
| 04/28/2004 | EP0910645B1 A KINASE CAPABLE OF SITE-SPECIFIC PHOSPHORYLATION OF I-kappa-B-alpha |
| 04/28/2004 | EP0896545B1 Method for producing drug containing hcv hyperimmune globulins |
| 04/28/2004 | EP0885309B1 Direct molecular diagnosis of friedreich ataxia |
| 04/28/2004 | EP0883993B1 Antiviral materials |
| 04/28/2004 | EP0856054B1 Monoclonal antibody br110 and uses thereof |
| 04/28/2004 | EP0805822B1 Spray dried erythropoietin |
| 04/28/2004 | EP0784682B1 Novel ectoparasite saliva proteins and apparatus to collect such proteins |
| 04/28/2004 | EP0730469B1 Modified truncated complement system regulators |
| 04/28/2004 | EP0698095B1 Bmp-10 compositions |
| 04/28/2004 | EP0655925B1 Anti-cancer therapeutic compositions containing whey protein concentrate |
| 04/28/2004 | EP0626861B2 Treatment for asthma |
| 04/28/2004 | EP0558648B1 Improved matrix metalloprotease inhibitors |
| 04/28/2004 | CN1493052A Method for identification of T-cell epitopes and use for preparing molecules with reduced immunogenicity |
| 04/28/2004 | CN1492929A Myocyte differentiation factor Fwa 267 |
| 04/28/2004 | CN1492928A Cell proliferation factor Fwap 10576 |
| 04/28/2004 | CN1492927A Human FGF23 protein mutant lowering blood phosphorus level |
| 04/28/2004 | CN1492926A Preferred segments of neural thread protein and methods of using the same |
| 04/28/2004 | CN1492876A Amphoteric sterols and the use thereof |
| 04/28/2004 | CN1492875A TTK in diagnosis and as a therapeutic target in cancer |
| 04/28/2004 | CN1492768A Artificial proteins with reduced immunogenicity |
| 04/28/2004 | CN1492767A Modified anti-EGFR antibody with reduced immunogenicity |
| 04/28/2004 | CN1492766A Prevention of diabetes by administration of GnRH antagonists |
| 04/28/2004 | CN1492758A Method and formula for anti-tumor and anti-matastatic effect |
| 04/28/2004 | CN1492756A Amphoteric liposomes and the use thereof |